Pain Relief Results After Anterior Cruciate Ligament (ACL) Reconstruction

May 2, 2013 updated by: University of Pittsburgh

Outcomes After ACL Reconstruction: The Effect of Femoral Nerve Block Analgesia

Anterior cruciate ligament (ACL) reconstruction is surgery that is done to repair a damaged ligament in the knee. In this study we will look at whether the femoral nerve block, a commonly used method for pain relief after ACL reconstruction, affects the way patients feel after surgery. We will study recovery during the first week after surgery and also 3-12 weeks after surgery. We will give all patients spinal anesthesia. Some patients will also receive a continuous femoral nerve block for 2 days, or by a single injection. We predict that patients who received the nerve block will have significantly improved pain results, compared to patients who did not receive the nerve block.

Study Overview

Detailed Description

In this project, we will measure outcomes of anesthesia and pain management for common orthopedic procedures. The influence of nerve block pain management on outcomes after outpatient anterior cruciate ligament (ACL) reconstruction has not been studied, especially the patient's potential to return to societal productivity during the first week after surgery. Therefore, we have designed a randomized clinical trial to study the role of nerve block pain management techniques on patient outcomes during the first week after surgery and on recovery 3-12 weeks after surgery. Our hypothesis is that patients undergoing nerve block analgesia will manifest better self-reported recovery outcomes, physical function outcomes, and objective measures of neuromuscular function.

We will give consenting patients (n=270) undergoing ACL reconstruction conventional spinal anesthesia and will randomize them to receive femoral nerve block analgesia with either a single injection, a continuous infusion for 2 days, or saline placebo. We will use goniometry to test postoperative range of motion in extension to determine whether the quadriceps femoris torque output is impaired. We will compare patient-reported recovery outcomes across treatment groups using three validated health status measures suitable for daily assessment (Verbal Pain Score, SF-8, and the Quality of Recovery [from anesthesia, QoR-40] Score).

We aim to determine the quality of immediate recovery from anesthesia and the extent of reported pain. We will compare the effects of single injection and continuous infusion on femoral nerve analgesia to determine the better dosing strategy for these patients.

Study Type

Interventional

Enrollment (Actual)

270

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15203
        • University of Pittsburgh Medical Center, Center for Sports Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 65 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 14-65
  • Undergoing ACL reconstruction at the University of Pittsburgh
  • Agrees to spinal anesthesia and consents to one of the three nerve block interventions.
  • Agrees to visit the University of Pittsburgh Center for Rehabilitation Services for postoperative physical therapy and rehabilitation (for standardized rehabilitation protocols)

Exclusion Criteria:

  • Morbid obesity
  • Chronic pain syndromes
  • Opioid dependence
  • Corticosteroid prescriptions
  • Tricyclic antidepressant prescriptions
  • Tramadol prescriptions
  • Preexisting neuropathies
  • Poorly controlled diabetes mellitus
  • Poorly controlled anxiety disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: 1
Nerve block bolus with 30 mL saline, followed by continuous saline infusion
EXPERIMENTAL: 2
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
EXPERIMENTAL: 3
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Pain scores during the first week after surgery
Time Frame: one week
one week

Secondary Outcome Measures

Outcome Measure
Time Frame
Side effects during the first week after surgery (nausea, vomiting, quality of sleep)
Time Frame: first week after surgery
first week after surgery
Determine the "rebound pain score" after a nerve block wears off
Time Frame: first week after surgery
first week after surgery
Skin reactions to the nerve block catehter dressing
Time Frame: first week after surgery
first week after surgery
Risk of falling
Time Frame: first week after surgery
first week after surgery
Validation of an 8-item outcome survey in comparison to a 40-item "gold standard" outcome survey
Time Frame: first week after surgery
first week after surgery
Study staffing costs before and after the implementation of HIPAA
Time Frame: the 40 months of study recruitment
the 40 months of study recruitment
Patient-reported general health status, and patient-reported knee function, during the first 12 weeks after surgery
Time Frame: up to 12 weeks after surgery
up to 12 weeks after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brian A. Williams, MD, MBA, University of Pittsburgh

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2001

Study Completion (ACTUAL)

January 1, 2005

Study Registration Dates

First Submitted

August 14, 2001

First Submitted That Met QC Criteria

August 15, 2001

First Posted (ESTIMATE)

August 16, 2001

Study Record Updates

Last Update Posted (ESTIMATE)

May 3, 2013

Last Update Submitted That Met QC Criteria

May 2, 2013

Last Verified

May 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • K23AR047631 (NIH)
  • NIAMS-066

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anterior Cruciate Ligament Rupture

Clinical Trials on Saline (control) injection into femoral nerve envelope

3
Subscribe